Compare CVS Health Corp (CVS) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Intel Corp — how do they compare? CVS Health Corp trades at $86.52 (market cap $112.29B), while Intel Corp trades at $106.38 (market cap $566.04B). The key difference: Intel Corp is far larger — about 5× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Intel Corp for 116 Days on average.
| CVS | INTC | |
|---|---|---|
Market Cap | $112.29B | $566.04B |
Volume | 7,763,676 | 118,475,837 |
Sector | Health | Technology |
52-Week High | $110.60 | $140.94 |
52-Week Low | $70.08 | $33.62 |
Typical Hold Time | 83 Days | 116 Days |
Enterprise Value | $174.64B | $586.85B |
Dividend Yield | 3.03% | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
Intel (INTC) trades at $113.12, up 0.55% on the day, with a bullish technical signal supported by moving averages. Recent earnings beats and a 222% stock surge in 2026 reflect strong AI momentum and foundry growth, though negative net income and high valuation ratios signal caution. The company's cash flow improved in 2025, but competitive pressures and margin challenges persist.
The outlook hinges on Intel's foundry turnaround gaining traction, with revenue growth and external customer adoption as key catalysts. Risks include intense competition, high debt, and execution uncertainty. Analyst consensus is mixed, with a hold rating dominant, suggesting cautious optimism amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
